MILESTONE PHARMACEUTICALS IN (MIST) Stock Analyst Earnings Estimates
NASDAQ:MIST - Nasdaq - CA59935V1076 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 15M | 5M -66.67% | 1M -80.00% | -100.00% | 4.692M | 56.559M 1,105.43% | 153.87M 172.05% | 249.54M 62.18% | 391.32M 56.82% | 547.74M 39.97% | 390.15M -28.77% | |
| EBITDA YoY % growth | -42.98M 15.08% | -59.55M -38.55% | -61.006M -2.45% | -38.76M 36.47% | -62.22M -60.53% | -72.318M -16.23% | 50.898M 170.38% | 88.944M 74.75% | 290.9M 227.06% | 527.34M 81.28% | N/A | |
| EBIT YoY % growth | -43.07M 15.07% | -59.64M -38.47% | -61.098M -2.44% | -41.018M 32.87% | -71.735M -74.89% | -40.749M 43.19% | 49.929M 222.53% | 101.08M 102.45% | 231.23M 128.76% | 373.47M 61.51% | 300.08M -19.65% | |
| Operating Margin | -287.13% | -1,192.80% | -6,109.80% | N/A | -1,528.87% | -72.05% | 32.45% | 40.51% | 59.09% | 68.18% | 76.91% | |
| EPS YoY % growth | -1.02 41.04% | -1.37 -34.31% | -1.39 -1.46% | -0.63 54.32% | -1.02 -61.04% | -0.36 65.09% | 0.97 371.43% | 1.85 90.53% | 2.61 41.44% | 3.15 20.70% | 3.69 17.15% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.16 51.39% | -0.21 1.64% | -0.24 -73.04% | -0.29 -104.00% | -0.29 -83.61% |
| Revenue Q2Q % growth | 849.997K | 2.808M | |||
| EBITDA Q2Q % growth | -8.466M 38.24% | -9.18M 12.14% | -11.73M -22.09% | -19.992M -109.63% | -21.318M -151.81% |
| EBIT Q2Q % growth | -10.659M 22.76% | -15.708M -49.94% | -18.802M -94.60% | -23.003M -139.22% | -24.567M -130.48% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.14 60.00% | -0.17 | 0.03 | 15.96% |
| Q2 2024 Q2Q % growth | -0.14 62.16% | -0.19 | 0.05 | 27.76% |
| Q1 2024 Q2Q % growth | -0.21 40.00% | -0.27 | 0.06 | 20.81% |
| Q4 2023 Q2Q % growth | -0.32 -3.23% | -0.32 | 0.00 | -0.39% |
| Q3 2023 Q2Q % growth | -0.35 -2.94% | -0.39 | 0.04 | 10.17% |
| Q2 2023 Q2Q % growth | -0.37 5.13% | -0.39 | 0.02 | 6.02% |
| Q1 2023 Q2Q % growth | -0.35 -6.06% | -0.41 | 0.06 | 13.78% |
| Q4 2022 Q2Q % growth | -0.31 22.50% | -0.34 | 0.03 | 9.28% |
| Q3 2022 Q2Q % growth | -0.34 | -0.42 | 0.08 | 18.30% |
| Q2 2022 Q2Q % growth | -0.39 -2,050.00% | -0.37 | -0.02 | -6.21% |
| Q1 2022 Q2Q % growth | -0.33 -10.00% | -0.40 | 0.07 | 17.04% |
| Q4 2021 Q2Q % growth | -0.40 -207.69% | -0.37 | -0.03 | -7.74% |
| Q3 2021 Q2Q % growth | -0.34 15.00% | -0.39 | 0.05 | 13.19% |
| Q2 2021 Q2Q % growth | 0.02 103.77% | -0.27 | 0.29 | 107.48% |
| Q1 2021 Q2Q % growth | -0.30 55.22% | -0.33 | 0.03 | 10.33% |
| Q4 2020 Q2Q % growth | -0.13 79.37% | -0.41 | 0.28 | 68.61% |
| Q3 2020 Q2Q % growth | -0.40 23.08% | -0.50 | 0.10 | 19.97% |
| Q2 2020 Q2Q % growth | -0.53 49.04% | -0.48 | -0.05 | -11.15% |
| Q1 2020 Q2Q % growth | -0.67 | -0.76 | 0.09 | 11.53% |
| Q4 2019 Q2Q % growth | -0.63 | -0.53 | -0.10 | -19.93% |
| Q3 2019 Q2Q % growth | -0.52 | -0.49 | -0.03 | -5.11% |
| Q2 2019 Q2Q % growth | -1.04 | -0.48 | -0.56 | -114.65% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2024 Q2Q % growth | -100.00% | % | ||
| Q4 2023 Q2Q % growth | -100.00% | % | ||
| Q3 2023 Q2Q % growth | -100.00% | % | ||
| Q4 2022 Q2Q % growth | 3.5M | 892.5K | 2.608M | 292.16% |
| Q2 2022 Q2Q % growth | -100.00% | % | ||
| Q2 2021 Q2Q % growth | 15M | 3.06M | 11.94M | 390.20% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 29.07% | 0% | 0.67% |
| Revenue | N/A | N/A | N/A | N/A |